- A company presentation at the H.C. Wainwright Annual
Global Investment Conference onWednesday, September 13, 2023 at10:00 a.m. ET . - A fireside chat at the
Cantor Global Healthcare Conference onTuesday, September 26, 2023 at2:10 p.m. ET . - A fireside chat at the Jefferies Cell & Genetic Medicine Summit on
Wednesday, September 27, 2023 at9:30 a.m. ET .
A live webcast of the presentation and fireside chats can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the events will also be available for a limited time.
About
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of our Biologics License Application submission to the FDA for EB-101; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the
Investor and Media Contact:Greg Gin VP, Investor Relations and Corporate CommunicationsAbeona Therapeutics ir@abeonatherapeutics.com
Source:
2023 GlobeNewswire, Inc., source